This is the authors' abstract. We don't add key points for this paper.
A major goal of the transplant field is to tolerize donor T cells to prevent graft-versus-host disease (GVHD) (1). We describe an ex vivo approach in which the blockade of CD40 ligand (CD40L:CD154):CD40 interactions, a pathway required for optimal T cell expansion, induces donor CD4(+) T cells to become tolerant to host alloantigens (2). High doses of tolerized cells did not cause GVHD lethality in vivo. T cells had intact responses to antigens not present during tolerization. Tolerance was long lived and not readily reversible in vivo. These data have significant implications for the use of tolerization approaches to prevent human GVHD.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Blazar et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: